Urine Cytology for Bladder Cancer Explained
Urine cytology examines shed urinary cells under a microscope for features of urothelial cancer. It is most useful for detecting high-grade bladder cancer and carcinoma in situ (CIS), but it is much less sensitive for low-grade papillary tumours. A “negative” cytology therefore does not rule out bladder cancer, and a “suspicious” or “positive” result does not identify the exact site—it may originate anywhere in the bladder, ureters or renal pelvis. Cytology complements cystoscopy and imaging; it does not replace them.
How is the sample collected?
A freshly voided urine sample can be sent to cytology; early-morning urine is often avoided because degenerated cells may reduce quality. In selected cases, bladder washings or selective upper-tract samples are obtained during cystoscopy/ureteroscopy.
Common report terms
- Negative for high-grade urothelial carcinoma
- Atypical urothelial cells
- Suspicious for high-grade urothelial carcinoma
- High-grade urothelial carcinoma
- Other/insufficient categories depending on laboratory system
Why low-grade tumours can be missed
Low-grade tumour cells often look relatively similar to normal urothelial cells even when a visible papillary tumour is present. Cystoscopy remains the primary method for detecting many papillary bladder recurrences.
What if cytology is positive but cystoscopy looks normal?
CIS can be subtle, and the abnormal cells may arise from the prostatic urethra or upper urinary tract. The urologist may use enhanced cystoscopy, mapping biopsies, upper-tract imaging/cytology or ureteroscopy according to the clinical situation.
Urine markers versus cytology
Commercial molecular urine tests can improve sensitivity in some settings but can generate false positives and do not routinely replace cystoscopy. Their role depends on risk group and surveillance pathway.
Cytology is better at finding dangerous disease than low-grade papillary tumours
Urine cytology is most useful for high-grade urothelial carcinoma and CIS because those cells shed marked malignant changes. Sensitivity is much lower for low-grade tumours, so a negative cytology cannot rule out a small papillary bladder cancer seen or suspected on cystoscopy.
“Atypical” is not the same as cancer
Inflammation, stones, instrumentation and intravesical therapy can produce atypical cells. Modern reporting systems distinguish negative, atypical, suspicious and high-grade categories. The result is interpreted with cystoscopy, imaging and previous pathology rather than used as an isolated diagnosis.
Positive cytology with a normal bladder needs a search for the source
If repeated cytology strongly suggests high-grade urothelial carcinoma but cystoscopy does not show a bladder tumour, evaluation may extend to enhanced cystoscopy, bladder biopsies, prostatic urethra in selected men and the upper urinary tracts. The abnormal cells can originate anywhere along the urothelium.
Cytology is strongest for the cancers cystoscopy can miss most easily
Urine cytology is much better at detecting high-grade urothelial carcinoma and CIS than low-grade papillary tumours. A negative result therefore cannot exclude bladder cancer, while a convincingly positive result with normal cystoscopy should prompt a search for occult CIS or upper-tract disease rather than being dismissed as a laboratory error. Instrumentation, stones and inflammation can produce atypical results, so the wording—negative, atypical, suspicious or positive—matters.
When to seek earlier medical review
Persistent positive/suspicious cytology should be reviewed even when cystoscopy is normal. Fever, clot retention or inability to pass urine after instrumentation is urgent; isolated “atypical” cytology without symptoms is usually handled through planned repeat evaluation.
Emergency warning signs
- Heavy bleeding with clots or inability to pass urine
- Fever, chills or severe urinary symptoms after TURBT/BCG
- New severe pelvic or flank pain with vomiting
- Shortness of breath, chest pain or sudden leg swelling after major surgery
What to bring to your consultation
- Urine cytology report with exact category
- Cystoscopy findings
- CT urography/upper-tract imaging if done
- Previous cytology reports for comparison
Questions to ask your doctor
- Is the cytology negative, atypical, suspicious or high-grade?
- Could recent BCG, infection or instrumentation explain the result?
- If cytology is positive but cystoscopy is normal, where will you look next?
FAQs
Can a urinary infection make cytology abnormal?
Yes. Infection, stones, instrumentation and treatment effects can cause atypical reactive changes.
Does negative cytology mean I do not have bladder cancer?
No. It is particularly poor at excluding low-grade tumours.
Why is cytology more useful for CIS?
CIS is high-grade and sheds markedly abnormal cells that are more readily recognised microscopically.
Can cytology tell whether the cancer is in the bladder or kidney?
Not reliably. Positive cells can come from any urothelial-lined site, so localisation requires cystoscopy and imaging/upper-tract evaluation.
Related reading
- Bladder Cancer: Symptoms and Treatment
- TURBT Explained
- Bladder Cancer Stages Explained: Ta, T1, T2 and Beyond
- Carcinoma in Situ (CIS) of the Bladder Explained
- BCG-Unresponsive Bladder Cancer: What Happens Next?
- Urologist in Latur
References
- European Association of Urology (EAU). Non-muscle-invasive Bladder Cancer Guidelines https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
- European Association of Urology (EAU). Muscle-invasive and Metastatic Bladder Cancer Guidelines. Disease Management https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/disease-management
- National Cancer Institute. Bladder Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq